Innate Immunotherapeutics

Innate Immunotherapeutics Limited is a medical biotechnology company with offices in Sydney and Auckland.
 
The Company is currently conducting a Phase 2B efficacy trial of its drug candidate (MIS416) in patients with secondary progressive multiple sclerosis (SPMS). There are currently no safe and effective ongoing treatments for this progressive and highly disabling form of multiple sclerosis.
 
On completion of this study, expected 2017, the Company’s strategy is to partner this clinical programme application with ‘big pharma’ to complete approval trials and launch sales into the worldwide unmet market for SPMS. 

Latest Media Releases

Innate Immunotherapeutics, Bioshares Edition 692

27/04/2017 14:05:00

Innate Completes Dosing in Phase IIb MS Trial Innate Immunotherapeutics (IIL: $0.77) has completed dosing the 93 patients participating in its Phase IIb secondary progressive multiple sclerosis (SP…

Latest News